Akums Drugs and Pharmaceuticals Ltd
Akums Drugs Reports Q2 FY27 Standalone Net Profit of Rs. 326.37 million
RESULTS
▲ Positive Development
MEDIUM RISK
📅 Filed on BSE: 02 Nov 2026, 05:27 PM IST · BSE ID: 2566a957-21be-4faa-9324-d611db024d3c
View Original BSE Filing (PDF)
💡
In Simple Terms
Akums Drugs announced its latest financial results, showing a net profit of Rs. 326.37 million for Q2 FY27 and full IPO fund use.
🤖 AI Summary
- Akums Drugs reported standalone net profit of Rs. 326.37 million for the quarter ended 30 September 2026 (Q2 FY27).
- Standalone revenue from operations was Rs. 3,950.47 million for Q2 FY27, compared to Rs. 3,093.15 million in Q2 FY26.
- The company confirmed 100% utilization of proceeds from its Initial Public Offer (IPO).
- Mr. Sanjay Kumar, President – Operations, was designated as a Senior Management Personnel by the Board.
- Standalone total comprehensive income for Q2 FY27 stood at Rs. 313.04 million.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Standalone Revenue from Operations (Q2 FY27)
3,950.47 million
Standalone Net Profit (Q2 FY27)
326.37 million
Standalone Revenue from Operations (H1 FY27)
7,873.21 million
Standalone Net Profit (H1 FY27)
774.76 million
Basic and Diluted EPS (Q2 FY27)
2.13
🏢 How This Affects the Company
The increase in revenue from operations for Q2 FY27 indicates continued business activity and market presence for Akums Drugs and Pharmaceuticals Limited.
The company's standalone net profit of Rs. 326.37 million for Q2 FY27 contributes to its overall financial performance. Full utilization of IPO proceeds clarifies capital deployment.
The designation of Mr. Sanjay Kumar as Senior Management Personnel strengthens the operational leadership structure of the company.
The full utilization of IPO proceeds, as per Regulation 32(2), reduces the reporting requirement for deviation statements for future quarters, decreasing regulatory compliance overhead.
👥 What This Means For Shareholders
✅
Action Required
No action is required from shareholders based on this financial results filing.
👤
Who Is Affected
All shareholders are affected by the company's financial performance and operational updates, including the designation of Mr. Sanjay Kumar as Senior Management Personnel.
🔍
Management Signal
Management's reporting of full IPO fund utilization and the designation of a key operational leader signals a focus on capital deployment and strengthening the organizational structure.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Q3 FY27 financial results — monitor revenue and profit trends.
Updates on the tax demand of Rs. 600.92 million mentioned in auditor's report.
Any further announcements regarding senior management changes or appointments.
MEDIUM RISK
A significant tax demand of Rs. 600.92 million from income-tax authorities is noted in the auditor's report.
💡 Investor Takeaway
Akums Drugs reported Q2 FY27 standalone net profit of Rs. 326.37 million on revenue from operations of Rs. 3,950.47 million. Half-year (H1 FY27) standalone net profit reached Rs. 774.76 million. The company confirmed 100% utilization of its IPO proceeds, reducing future compliance requirements.
⚖️ Strengths & Concerns
✅ Positives
- Standalone revenue from operations for Q2 FY27 increased to Rs. 3,950.47 million, up from Rs. 3,093.15 million in Q2 FY26.
- Net profit for the half-year ended 30 September 2026 (H1 FY27) increased to Rs. 774.76 million from Rs. 683.29 million in H1 FY26.
⚠️ Concerns
- Profit before tax for Q2 FY27 declined to Rs. 438.48 million from Rs. 593.36 million in Q1 FY27 (quarter ended 30 June 2026).
- Other comprehensive income for Q2 FY27 recorded a net loss of Rs. 13.33 million, compared to a gain of Rs. 10.54 million in Q1 FY27.
📅 Company Track Record
Akums Drugs reported a standalone net profit of Rs. 326.37 million for Q2 FY27, building on its Q2 FY26 net profit of Rs. 234.62 million. In its previous filing, the company reported Q4 FY26 standalone net profit of Rs. 326.37 million and proposed a Rs. 3.00 per share dividend.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What was Akums Drugs and Pharmaceuticals Limited's standalone net profit for Q2 FY27?
Akums Drugs and Pharmaceuticals Limited reported a standalone net profit of Rs. 326.37 million for the quarter ended 30 September 2026 (Q2 FY27).
What was Akums Drugs and Pharmaceuticals Limited's standalone revenue from operations in Q2 FY27?
The standalone revenue from operations for Akums Drugs and Pharmaceuticals Limited was Rs. 3,950.47 million for Q2 FY27 (quarter ended 30 September 2026).
Has Akums Drugs and Pharmaceuticals Limited fully utilized its IPO proceeds?
Yes, Akums Drugs and Pharmaceuticals Limited has fully utilized 100% of the proceeds from its Initial Public Offer.
Who was designated as Senior Management Personnel by Akums Drugs and Pharmaceuticals Limited?
Mr. Sanjay Kumar, President – Operations, was designated as Senior Management Personnel of Akums Drugs and Pharmaceuticals Limited by the Board of Directors.
What is the tax demand mentioned in Akums Drugs and Pharmaceuticals Limited's auditor's report?
The auditor's report draws attention to a tax demand of Rs. 600.92 million raised by income-tax authorities for the block period from 01 April 2018 to 12 March 2025.
Questions based on this BSE filing only. For information purposes.